The article focuses on the potential new therapies for metastatic melanoma. It is stated that Ipilimumab and Vemurafenib (PLX4032) drugs are used for the treatment of advance and late stage melanoma respectively. Side effects of Ipilimumab including fatigue, diarrhea, skin rash and endocrine deficiencies are also reported.